No sign of stopping: The rise of cell and gene therapy
Drug Discovery World
MAY 22, 2023
But are these price tags a barrier to access? Looking forward Automation might be the solution to the lack of skilled personnel. Advanced Therapies Week highlights the dynamic landscape of CGTs. million per dose. Simply, yes, as we saw when the European Commission rejected the price point for bluebird bio’s Zynteglo.
52 
Let's personalize your content